Program
envudeucitinib
Also written as “ESK-001”, “Envudeucitinib” and “Open-Label Envudeucitinib”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Renal Insufficiency · Uveitis, Intermediate, led by Alumis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alumis | 123 open or running | phase 3since Aug 14, 2024 | Mar 30, 2022 | Dec 1, 2027phase 2 · NCT05739435 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2022First study: phase 1 study in PharmacokineticsFirst studyNCT05330858 · 14 enrolled · United States
- Jun 9, 2022Phase 1 study in Safety and TolerabilityNCT05431634 · 49 enrolled · United States
- Oct 12, 2022Phase 2 study in Plaque PsoriasisNCT05600036 · 228 enrolled · United States, Canada, Czechia
- Feb 2, 2023Phase 2 study in Plaque PsoriasisNCT05739435 · 165 enrolled · United States, Canada
- Jun 29, 20232 phase 2 studiesNCT05966480, NCT05953688
- Aug 14, 2024Phase 3 study in Plaque PsoriasisNCT06586112 · 912 enrolled · United States, Australia, Bulgaria and more
- Sep 7, 2024Phase 3 study in Plaque PsoriasisNCT06588738 · 862 enrolled · United States, Austria, Canada and more
- Jan 27, 2025Phase 3 study in PsoriasisNCT06846541 · 1,680 enrolled · United States, Australia, Bulgaria and more
- Apr 22, 20252 phase 1 studiesNCT06952634, NCT06962774
- Dec 10, 2025Phase 1 study in Healthy VolunteerNCT07378579 · 52 enrolled · United States
Ahead
- Dec 1, 2027Primary completion: phase 2 study in Plaque PsoriasisNCT05739435
- Nov 2028Primary completion: phase 3 study in PsoriasisNCT06846541
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07378579Healthy Volunteer · United States | 1 | Completed | Aug 31, 2024 | 52 |
| NCT06962774Renal Insufficiency · United States | 1 | Completed | Aug 1, 2025 | 16 |
| NCT06952634Hepatic Impairment · United States | 1 | Completed | Mar 24, 2026 | 32 |
| NCT06846541Psoriasis · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Nov 2028 | 1,680 |
| NCT06588738Plaque Psoriasis · United States, Austria, Canada and more | 3 | Completed | Sep 23, 2025 | 862 |
| NCT06586112Plaque Psoriasis · United States, Australia, Bulgaria and more | 3 | Completed | Sep 19, 2025 | 912 |
| NCT05966480Autoimmune Diseases · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Jun 23, 2026 | 408 |
| NCT05953688Uveitis, Intermediate · United States | 2 | Terminated | Aug 13, 2024 | 36 |
| NCT05739435Plaque Psoriasis · United States, Canada | 2 | Active, not recruiting | Dec 1, 2027 | 165 |
| NCT05600036Plaque Psoriasis · United States, Canada, Czechia | 2 | Completed | Jun 29, 2023 | 228 |
| NCT05431634Safety and Tolerability · United States | 1 | Completed | Dec 1, 2022 | 49 |
| NCT05330858Pharmacokinetics · United States | 1 | Completed | Jun 30, 2022 | 14 |
How it is read
Names in the registry
- “ESK-001”, 5 entries
- “Envudeucitinib”, 3 entries
- “envudeucitinib”, 2 entries
- “Open-Label Envudeucitinib”, 1 entry
- “Experimental drug: ESK-001”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 5 studies
- Lupus Erythematosus, Systemic, 1 study
- Renal Insufficiency, 1 study
- Uveitis, Intermediate, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.